

according to the formula  $R^1\text{-COO}^+\text{M}^+$ , wherein  $R^1$  comprises  $\text{CH}_3\text{-(CH}_2)_7\text{-CH=CH-CH}_2\text{-(CH}_2)_x$ , and  $x$  is 6, 8, 10 and 12 and  $\text{M}^+$  is a monovalent alkali metal ion.

- A1  
only
3. The method according to claim 2 wherein the composition further comprises one or more of the mixed esters according to the formula  $R^1\text{-COO-R}^2$ , wherein  $R^1$  comprises  $\text{CH}_3\text{-(CH}_2)_7\text{-CH=CH-CH}_2\text{-(CH}_2)_x$ , and  $x$  is 6, 8, 10 and 12, and  $R^2$  is an alkyl group or other aliphatic group, preferably of 1 to 12 carbon atoms.
- 

4. (Canceled)

5. The method of claim 2 wherein said alcohols are comprised of relative proportions of octadecenol is about 1%, eicosenol is about 44%, docosenol is about 45%, and tetracosenol is about 9%.

6. The method of claim 3 wherein said alcohols are comprised of relative proportions of octadecenol is about 1%, eicosenol is about 44%, docosenol is about 45%, and tetracosenol is about 9%.

7. (Canceled)

---

- A2
8. A method treating virus-induced and inflammatory diseases of skin and membranes in humans or animals, comprising topical application of a composition comprising of one or more of the monounsaturated alcohols docosenol, tetracosenol and hexacosenol in a concentration of from 0.1 to 25 percent by weight in a concentration of from 0.1 to 25 percent by weight, all in a physiologically compatible carrier to the inflamed skin or membrane of the patient to be treated, the composition further comprising

one or more of the salts of fatty acids according to the formula  $R^1\text{-COO}^-M^+$ , wherein  $R^1$  comprises  $\text{CH}_3\text{-(CH}_2)_7\text{-CH=CH-CH}_2\text{-(CH}_2)_x$ , and  $x$  is 6, 8, 10 and 12 and  $M^+$  is a monovalent alkali metal ion.

- A2  
Canceled
9. The method of claim 8 wherein the composition further comprises mixed esters according to the formula  $R^1\text{-COO-R}^2$ , wherein  $R^1$  comprises  $\text{CH}_3\text{-(CH}_2)_7\text{-CH=CH-CH}_2\text{-(CH}_2)_x$ , and  $x$  is 6, 8, 10 and 12, and  $R^2$  is an alkyl group or other aliphatic group, preferably of 1 to 12 carbon atoms.
- 

10. (Canceled)

---

- A3
11. The method of claim 8 wherein said alcohols are comprised of relative proportions of octadecenol is about 1%, docosenol is about 45%, and tetracosenol is about 9%.

12. The method of claim 9 wherein said alcohols are comprised of relative proportions of octadecenol is about 1%, docosenol is about 45%, and tetracosenol is about 9%.
- 

13. (Canceled)

---

- A4
14. A method of treating humans or other mammals for viral infections, comprising intravenous introduction into the human or other mammal suspected of having a viral infection with an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a composition consisting of one or more  $\text{C}_{18}$  to  $\text{C}_{24}$  monounsaturated alcohols in a physiologically compatible carrier, the composition further comprising one or more of the salts of fatty acids according to the formula  $R^1\text{-COO}^-$

*Ad Contd*

$M^+$ , wherein  $R^1$  comprises  $CH_3-(CH_2)_7-CH=CH-CH_2-(CH_2)_x-$ , and  $x$  is 6, 8, 10 and 12 and  $M^+$  is a monovalent alkali metal ion.

15. The method of claim 14 wherein the composition further comprises mixed esters according to the formula  $R^1-COO-R^2$ , wherein  $R^1$  comprises  $CH_3-(CH_2)_7-CH=CH-CH_2-(CH_2)_x-$ , and  $x$  is 6, 8, 10 and 12, and  $R^2$  is an alkyl group or other aliphatic group, preferably of 1 to 12 carbon atoms.
- 

16. (Canceled)

17. The method of claim 14 wherein said alcohols are comprised of relative proportions of octadecenol is about 1%, eicosenol is about 44%, docosenol is about 45%, and tetracosenol is about 9%.

18. The method of claim 15 wherein said alcohols are comprised of relative proportions of octadecenol is about 1%, eicosenol is about 44%, docosenol is about 45%, and tetracosenol is about 9%.

19. (Canceled)

---

- AS*
20. A method of treating humans or other mammals for viral infections, comprising intramuscular introduction into the human or other mammal suspected of having a viral infection with an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a composition consisting of one or more  $C_{18}$  to  $C_{24}$  monounsaturated alcohols in a physiologically compatible carrier, the composition further comprising one or more of the salts of fatty acids according to the formula  $R^1-COO^-M^+$ , wherein  $R^1$  comprises  $CH_3-(CH_2)_7-CH=CH-CH_2-(CH_2)_x-$ , and  $x$  is 6, 8, 10 and 12 and  $M^+$  is a monovalent alkali metal ion.

AS Conty

21. The method of claim 20 wherein the composition further comprises mixed esters according to the formula  $R^1\text{-COO-R}^2$ , wherein  $R^1$  comprises  $\text{CH}_3\text{-(CH}_2)_7\text{-CH=CH-CH}_2\text{-(CH}_2)_x$ , and  $x$  is 6, 8, 10 and 12, and  $R^2$  is an alkyl group or other aliphatic group, preferably of 1 to 12 carbon atoms.

---

22. (Canceled)

23. The method of claim 20 wherein said alcohols are comprised of relative proportions of octadecenol is about 1%, eicosenol is about 44%, docosenol is about 45%, and tetracosenol is about 9%.

24. The method of claim 21 wherein said alcohols are comprised of relative proportions of octadecenol is about 1%, eicosenol is about 44%, docosenol is about 45%, and tetracosenol is about 9%.

25. (Canceled)

---

Al

26. A method of treating humans or other mammals for viral infections, comprising trans-mucus membranal introduction into the human or other mammal suspected of having a viral infection with an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a composition consisting of one or more  $\text{C}_{18}$  to  $\text{C}_{24}$  monounsaturated alcohols in a physiologically compatible carrier, the composition further comprising one or more of the salts of fatty acids according to the formula  $R^1\text{-COO}^-\text{M}^+$ , wherein  $R^1$  comprises  $\text{CH}_3\text{-(CH}_2)_7\text{-CH=CH-CH}_2\text{-(CH}_2)_x$ , and  $x$  is 6, 8, 10 and 12 and  $\text{M}^+$  is a monovalent alkali metal ion.

27. The method of claim 26 wherein the composition further comprises mixed esters according to the formula  $R^1\text{-COO-R}^2$ , wherein  $R^1$  comprises  $\text{CH}_3\text{-}$

*File Contd*

$(CH_2)_7-CH=CH-CH_2-(CH_2)_x$ , and  $x$  is 6, 8, 10 and 12, and  $R^2$  is an alkyl group or other aliphatic group, preferably of 1 to 12 carbon atoms.

28. (Canceled)
29. The method of claim 26 wherein said alcohols are comprised of relative proportions of octadecenol is about 1%, eicosenol is about 44%, docosenol is about 45%, and tetracosenol is about 9%.
30. The method of claim 27 wherein said alcohols are comprised of relative proportions of octadecenol is about 1%, eicosenol is about 44%, docosenol is about 45%, and tetracosenol is about 9%.
31. (Canceled)
32. A method of treating humans or other mammals for viral infections, comprising transdermal penetration into the human or other mammal suspected of having a viral infection with an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a composition consisting of one or more  $C_{18}$  to  $C_{24}$  monounsaturated alcohols in a physiologically compatible carrier, the composition further comprising one or more of the salts of fatty acids according to the formula  $R^1-COO^-M^+$ , wherein  $R^1$  comprises  $CH_3-(CH_2)_7-CH=CH-CH_2-(CH_2)_x$ , and  $x$  is 6, 8, 10 and 12 and  $M^+$  is a monovalent alkali metal ion.
33. The method of claim 32 wherein the composition further comprises mixed esters according to the formula  $R^1-COO-R^2$ , wherein  $R^1$  comprises  $CH_3-(CH_2)_7-CH=CH-CH_2-(CH_2)_x$ , and  $x$  is 6, 8, 10 and 12, and  $R^2$  is an alkyl group or other aliphatic group, preferably of 1 to 12 carbon atoms.

*A 7*

34. (Canceled)
35. The method of claim 32 wherein said alcohols are comprised of relative proportions of octadecenol is about 1%, eicosenol is about 44%, docosenol is about 45%, and tetracosenol is about 9%.
36. The method of claim 33 wherein said alcohols are comprised of relative proportions of octadecenol is about 1%, eicosenol is about 44%, docosenol is about 45%, and tetracosenol is about 9%.
37. (Canceled)
- 
38. A method of preventing or inhibiting the infection of humans or other mammals for viral infections, comprising intravenous introduction into the human or other mammal suspected of having a viral infection with an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a composition consisting of one or more  $C_{18}$  to  $C_{24}$  monounsaturated alcohols in a physiologically compatible carrier, the composition further comprising one or more of the salts of fatty acids according to the formula  $R^1-COO^+M^+$ , wherein  $R^1$  comprises  $CH_3-(CH_2)_7-CH=CH-CH_2-(CH_2)_x$ , and  $x$  is 6, 8, 10 and 12 and  $M^+$  is a monovalent alkali metal ion.
39. The method of claim 38 wherein the composition further comprises mixed esters according to the formula  $R^1-COO-R^2$ , wherein  $R^1$  comprises  $CH_3-(CH_2)_7-CH=CH-CH_2-(CH_2)_x$ , and  $x$  is 6, 8, 10 and 12, and  $R^2$  is an alkyl group or other aliphatic group, preferably of 1 to 12 carbon atoms.
- 
40. (Canceled)

41. The method of claim 38 wherein said alcohols are comprised of relative proportions of octadecenol is about 1%, eicosenol is about 44%, docosenol is about 45%, and tetracosenol is about 9%.
42. The method of claim 39 wherein said alcohols are comprised of relative proportions of octadecenol is about 1%, eicosenol is about 44%, docosenol is about 45%, and tetracosenol is about 9%.
43. (Canceled)
- 
44. A method of preventing or inhibiting the infection of humans or other mammals for viral infections, comprising intramuscular introduction into the human or other mammal suspected of having a viral infection with an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a composition consisting of one or more  $C_{18}$  to  $C_{24}$  monounsaturated alcohols in a physiologically compatible carrier, the composition further comprising one or more of the salts of fatty acids according to the formula  $R^1-COO^+M^+$ , wherein  $R^1$  comprises  $CH_3-(CH_2)_7-CH=CH-CH_2-(CH_2)_x$ , and  $x$  is 6, 8, 10 and 12 and  $M^+$  is a monovalent alkali metal ion.
45. The method of claim 44 wherein the composition further comprises mixed esters according to the formula  $R^1-COO-R^2$ , wherein  $R^1$  comprises  $CH_3-(CH_2)_7-CH=CH-CH_2-(CH_2)_x$ , and  $x$  is 6, 8, 10 and 12, and  $R^2$  is an alkyl group or other aliphatic group, preferably of 1 to 12 carbon atoms.
- 
46. (Canceled)

47. The method of claim 44 wherein said alcohols are comprised of relative proportions of octadecenol is about 1%, eicosenol is about 44%, docosenol is about 45%, and tetracosenol is about 9%.

48. The method of claim 45 wherein said alcohols are comprised of relative proportions of octadecenol is about 1%, eicosenol is about 44%, docosenol is about 45%, and tetracosenol is about 9%.

49. (Canceled)

---

AIN 50. A method of preventing or inhibiting the infection of humans or other mammals, comprising trans-mucus membranal introduction into the human or other mammal suspected of having a viral infection with an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a composition consisting of one or more  $C_{18}$  to  $C_{24}$  monounsaturated alcohols in a physiologically compatible carrier, the composition further comprising one or more of the salts of fatty acids according to the formula  $R^1-COO^+M^+$ , wherein  $R^1$  comprises  $CH_3-(CH_2)_7-CH=CH-CH_2-(CH_2)_x$ , and  $x$  is 6, 8, 10 and 12 and  $M^+$  is a monovalent alkali metal ion.

51. The method of claim 50 wherein the composition further comprises mixed esters according to the formula  $R^1-COO-R^2$ , wherein  $R^1$  comprises  $CH_3-(CH_2)_7-CH=CH-CH_2-(CH_2)_x$ , and  $x$  is 6, 8, 10 and 12, and  $R^2$  is an alkyl group or other aliphatic group, preferably of 1 to 12 carbon atoms.

---

52. (Canceled)



53. The method of claim 50 wherein said alcohols are comprised of relative proportions of octadecenol is about 1%, eicosenol is about 44%, docosenol is about 45%, and tetracosenol is about 9%.
54. The method of claim 51 wherein said alcohols are comprised of relative proportions of octadecenol is about 1%, eicosenol is about 44%, docosenol is about 45%, and tetracosenol is about 9%.

55. (Canceled)

---

56. A method of preventing or inhibiting the infection of humans or other mammals, comprising transdermal penetration into the human or other mammal suspected of having a viral infection with an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a composition consisting of one or more  $C_{18}$  to  $C_{24}$  monounsaturated alcohols in a physiologically compatible carrier, the composition further comprising one or more of the salts of fatty acids according to the formula  $R^1-COO^+M^+$ , wherein  $R^1$  comprises  $CH_3-(CH_2)_7-CH=CH-CH_2-(CH_2)_x-$ , and  $x$  is 6, 8, 10 and 12 and  $M^+$  is a monovalent alkali metal ion.
57. The method of claim 56 wherein the composition further comprises mixed esters according to the formula  $R^1-COO-R^2$ , wherein  $R^1$  comprises  $CH_3-(CH_2)_7-CH=CH-CH_2-(CH_2)_x-$ , and  $x$  is 6, 8, 10 and 12, and  $R^2$  is an alkyl group or other aliphatic group, preferably of 1 to 12 carbon atoms.
- 

58. (Canceled)

59. The method of claim 56 wherein said alcohols are comprised of relative proportions of octadecenol is about 1%, eicosenol is about 44%, docosenol is about 45%, and tetracosenol is about 9%.
60. The method of claim 57 wherein said alcohols are comprised of relative proportions of octadecenol is about 1%, eicosenol is about 44%, docosenol is about 45%, and tetracosenol is about 9%.
61. (Canceled)

- A12
62. A physiologically compatible solution which can be injected into humans or other mammals for viral infections intravenously or intramuscularly consisting essentially of a composition consisting of one or more  $C_{18}$  to  $C_{24}$  monounsaturated alcohols in a physiologically compatible, intravenously or intramuscularly injectable carrier, the composition further comprising one or more of the salts of fatty acids according to the formula  $R^1-COO^+M^+$ , wherein  $R^1$  comprises  $CH_3-(CH_2)_7-CH=CH-CH_2-(CH_2)_x-$ , and  $x$  is 6, 8, 10 and 12 and  $M^+$  is a monovalent alkali metal ion.
63. The method of claim 62 wherein the composition further comprises mixed esters according to the formula  $R^1-COO-R^2$ , wherein  $R^1$  comprises  $CH_3-(CH_2)_7-CH=CH-CH_2-(CH_2)_x-$ , and  $x$  is 6, 8, 10 and 12, and  $R^2$  is an alkyl group or other aliphatic group, preferably of 1 to 12 carbon atoms.

64. (Canceled)

- A13
65. The method of claim 62 wherein said alcohols are comprised of relative proportions of octadecenol is about 1%, eicosenol is about 44%, docosenol is about 45%, and tetracosenol is about 9%.

A13  
Cm  
66. The method of claim 63 wherein said alcohols are comprised of relative proportions of octadecenol is about 1%, eicosenol is about 44%, docosenol is about 45%, and tetracosenol is about 9%.

---

67. (Canceled)

---

A14  
68. A physiologically compatible transdermal medication for introduction through the mucous membranes into humans or other mammals for viral infections consisting essentially of a composition consisting of one or more C<sub>18</sub> to C<sub>24</sub> monounsaturated alcohols and a penetration-enhancing compound, the composition further comprising one or more of the salts of fatty acids according to the formula R<sup>1</sup>-COO<sup>-</sup>M<sup>+</sup>, wherein R<sup>1</sup> comprises CH<sub>3</sub>-(CH<sub>2</sub>)<sub>7</sub>-CH=CH-CH<sub>2</sub>-(CH<sub>2</sub>)<sub>x</sub>, and x is 6, 8, 10 and 12 and M<sup>+</sup> is a monovalent alkali metal ion.

69. The method of claim 68 wherein the composition further comprises mixed esters according to the formula R<sup>1</sup>-COO-R<sup>2</sup>, wherein R<sup>1</sup> comprises CH<sub>3</sub>-(CH<sub>2</sub>)<sub>7</sub>-CH=CH-CH<sub>2</sub>-(CH<sub>2</sub>)<sub>x</sub>, and x is 6, 8, 10 and 12, and R<sup>2</sup> is an alkyl group or other aliphatic group, preferably of 1 to 12 carbon atoms.

---

70. (Canceled)

---

71. The method of claim 68 wherein said alcohols are comprised of relative proportions of octadecenol is about 1%, eicosenol is about 44%, docosenol is about 45%, and tetracosenol is about 9%.

72. The method of claim 69 wherein said alcohols are comprised of relative proportions of octadecenol is about 1%, eicosenol is about 44%, docosenol is about 45%, and tetracosenol is about 9%.

73. (Canceled)

---

AKS 74. A method of preventing conception and reducing the risk of viral infection comprising introducing a composition consisting essentially of one or more monounsaturated alcohols having from 18 to 24 carbons in a suitable carrier into the vagina substantially contemporaneously with or before intercourse, the composition further comprising one or more of the salts of fatty acids according to the formula  $R^1\text{-COO}^-\text{M}^+$ , wherein  $R^1$  comprises  $\text{CH}_3\text{-(CH}_2)_7\text{-CH=CH-CH}_2\text{-(CH}_2)_x\text{-}$ , and  $x$  is 6, 8, 10 and 12 and  $\text{M}^+$  is a monovalent alkali metal ion.

75. The method of claim 74 wherein the composition further comprises mixed esters according to the formula  $R^1\text{-COO-R}^2$ , wherein  $R^1$  comprises  $\text{CH}_3\text{-(CH}_2)_7\text{-CH=CH-CH}_2\text{-(CH}_2)_x\text{-}$ , and  $x$  is 6, 8, 10 and 12, and  $R^2$  is an alkyl group or other aliphatic group, preferably of 1 to 12 carbon atoms.

---

76. (Canceled)

77. The method of claim 74 wherein said alcohols are comprised of relative proportions of octadecenol is about 1%, eicosenol is about 44%, docosenol is about 45%, and tetracosenol is about 9%.

78. The method of claim 75 wherein said alcohols are comprised of relative proportions of octadecenol is about 1%, eicosenol is about 44%, docosenol is about 45%, and tetracosenol is about 9%.

79. (Canceled)

---

AK6 80. An anti-viral suppository for trans-membranal introduction into the vagina or anus of a human or other mammal of a composition consisting

essentially of one or more monounsaturated alcohols having from 18 to 24 carbons in a physiologically acceptable carrier which is a solid at ambient room temperature and which melts at approximately 37 °C, the composition further comprising one or more of the salts of fatty acids according to the formula  $R^1\text{-COO}^-\text{M}^+$ , wherein  $R^1$  comprises  $\text{CH}_3\text{-(CH}_2)_7\text{-CH=CH-CH}_2\text{-(CH}_2)_x\text{-}$ , and  $x$  is 6, 8, 10 and 12 and  $\text{M}^+$  is a monovalent alkali metal ion.

81. The method of claim 80 wherein the composition further comprises mixed esters according to the formula  $R^1\text{-COO-R}^2$ , wherein  $R^1$  comprises  $\text{CH}_3\text{-(CH}_2)_7\text{-CH=CH-CH}_2\text{-(CH}_2)_x\text{-}$ , and  $x$  is 6, 8, 10 and 12, and  $R^2$  is an alkyl group or other aliphatic group, preferably of 1 to 12 carbon atoms.

82. (Canceled)

83. The method of claim 80 wherein said alcohols are comprised of relative proportions of octadecenol is about 1%, eicosenol is about 44%, docosenol is about 45%, and tetracosenol is about 9%.

84. The method of claim 81 wherein said alcohols are comprised of relative proportions of octadecenol is about 1%, eicosenol is about 44%, docosenol is about 45%, and tetracosenol is about 9%.

85. (Canceled)

86. A method of treating humans and mammals for viral infections comprising introducing a composition consisting essentially of one or more monounsaturated alcohols having from 18 to 24 carbons through a membrane into the circulatory system of a human or mammal suspected of

A17  
Cmkt

having a viral infection with an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight comprising inserting such alcohol composition in a physiologically acceptable liquid, cream, gel or suppository carrier into the anus or vagina of the human or mammal to be treated, the composition further comprising one or more of the salts of fatty acids according to the formula  $R^1\text{-COO}^-\text{M}^+$ , wherein  $R^1$  comprises  $\text{CH}_3\text{-(CH}_2)_7\text{-CH=CH-CH}_2\text{-(CH}_2)_x\text{-}$ , and  $x$  is 6, 8, 10 and 12 and  $\text{M}^+$  is a monovalent alkali metal ion.

87. The method of claim 86 wherein the composition further comprises mixed esters according to the formula  $R^1\text{-COO-R}^2$ , wherein  $R^1$  comprises  $\text{CH}_3\text{-(CH}_2)_7\text{-CH=CH-CH}_2\text{-(CH}_2)_x\text{-}$ , and  $x$  is 6, 8, 10 and 12, and  $R^2$  is an alkyl group or other aliphatic group, preferably of 1 to 12 carbon atoms.

---

88. (Canceled)

89. The method of claim 86 wherein said alcohols are comprised of relative proportions of octadecenol is about 1%, eicosenol is about 44%, docosenol is about 45%, and tetracosenol is about 9%.

90. The method of claim 87 wherein said alcohols are comprised of relative proportions of octadecenol is about 1%, eicosenol is about 44%, docosenol is about 45%, and tetracosenol is about 9%.